J&J: Janssen signs schizophrenia contract with Oklahoma
(CercleFinance.com) - Johnson & Johnson's biopharmaceutical unit Janssen has signed a contract with Oklahoma's Medicaid plan focusing on the use of its long-acting injectable schizophrenia medicines, the drugmaker said on Thursday.
The arrangement with the Oklahoma Health Care Authority aims to improve care by enabling the use of Janssen's Invega Sustenna and Invega Trinza earlier in treatment of adults with schizophrenia, J&J said.
Data shows that Invega Sustenna was associated with a 36% reduction the in risk of hospitalization, compared to oral antipsychotics, over a 12-month period, meaning reduced expenses for medical services for Medicaid.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
The arrangement with the Oklahoma Health Care Authority aims to improve care by enabling the use of Janssen's Invega Sustenna and Invega Trinza earlier in treatment of adults with schizophrenia, J&J said.
Data shows that Invega Sustenna was associated with a 36% reduction the in risk of hospitalization, compared to oral antipsychotics, over a 12-month period, meaning reduced expenses for medical services for Medicaid.
Copyright (c) 2018 CercleFinance.com. All rights reserved.